A combinatorial platform for the discovery of novel macrocyclic peptide ligands against disease-relevant targets.
De novo discovery (hit identification)
Arzanya leverages proprietary yeast-displayed libraries integrated with advanced flow cytometry to identify novel macrocyclic peptide ligands. Our platform is engineered to discover molecules with high affinity and exquisite selectivity against a broad range of therapeutic targets.
Enhancing properties (lead optimization)
Arzanya employs focused library design and guided iterative selection strategies to enhance the potency and stability of existing peptide ligands. Through our rigorous hit-to-lead optimization process, we refine the biochemical properties of existing candidates to ensure they meet the stringent requirements of therapeutic development.
The platform
Our workflow
001
Scale
Proprietary naïve or tailored libraries of billions of diverse macrocyclic peptide ligands
002
Screening
Precise and quantitative high-throughput screening against multiple targets in parallel
003
Analysis
Rapid, quantitative characterization of cell-based binding properties
004
Hits
Robust synthesis of the most promising "hits," followed by rigorous biochemical and biophysical characterization
005
Lead
Integrated in vitro and in silico "hit-to-lead" optimization.
Do you need more information?